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Recognizing Phenotypes, Exploring Genotypes*Alan C. Braverman, MDSEE PAGE 1324T he discovery of a thoracic aortic aneurysm(TAA) or aortic dissection requires evaluationof relatives for similar disease because
20% will have an affected relative. Heritable TAA dis-
eases are due to mutations in a number of genes that
affect the aorta and its branches with differing
severity. Many disorders are associated with well-
characterized syndromic features (e.g., Marfan syn-
drome [MFS]), whereas others predominantly involve
the thoracic aorta, occasionally associated with
cerebral aneurysm or bicuspid aortic valve (1,2). Her-
itable TAA syndromes may be classiﬁed based on
the speciﬁc genes mutated, involving extracellular
matrix proteins, the transforming growth factor
(TGF)-b signaling pathway, vascular smooth muscle
cytoskeleton or contractile elements, or other
signaling pathways (1,2) (Table 1).
MFS, as a result of mutations in FBN1, is perhaps
the most well-recognized aneurysm syndrome, and
involves the aorta and heart, eyes, skeleton, lung, and
dura. Evidence for increased TGF-b signaling in
diseased tissues (lung, aorta, and mitral valve) was
recognized in the mouse model (3). TGF-b neutral-
izing antibody or angiotensin-1 receptor blocker
administration rescued the phenotype, providing
further evidence that abnormal TGF-b signaling is
important in pathogenesis.
In 2005, mutations in the genes encoding the re-
ceptors for TGF-b (TGFBR1 and TGFBR2) were recog-
nized as causing a multisystem aneurysm disease,
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arterial tortuosity, and early and aggressive aortic
and branch vessel disease (4). Newly characterized
familial TAA syndromes that are due to mutations in
other genes regulating TGF-b signaling were recently
discovered, including disorders as a result of muta-
tions in SMAD3, which share features with LDS, but
also with osteoarthritis, and mutations in the gene
encoding TGFB2 ligand (TGFB2), which has features
overlapping those in LDS and MFS (1,2). In this issue
of the Journal, Bertoli-Avella et al. (5) report the
features of an aortic aneurysm syndrome due to
mutations in TGFB3, which shares features of other
conditions (such as LDS and MFS) that are due to
perturbations in the TGF-b signaling pathway.Mutations in vascular smooth muscle contractile
element and cytoskeletal genes also cause TAA dis-
ease. Smooth muscle alpha-actin (ACTA2) mutations
cause 14% of familial TAA disease cases, and have
features including livedo reticularis, iris ﬂocculi,
premature coronary and cerebrovascular disease,
patent ductus arteriosus, Moyamoya disease, and
bicuspid aortic valve (6). MYLK and PRKG1 gene
mutations predominantly lead to TAA disease,
whereas MYH11 mutations may also be associated
with patent ductus arteriosus (1,2).
When managing the patient with a heritable TAA
syndrome, recognition of the speciﬁc disease and
mutation present are important because aortic and
branch vessel prognosis varies depending on the
mutated gene. Many families with TAA disease who
undergo mutation analysis will not have a pathogenic
gene mutation identiﬁed. However, discovery of
novel gene mutations in TAA disease is continuing
at a rapid pace. Familial TAA diseases are notable
for having marked interfamilial and intrafamilial
TABLE 1 Heritable TAA Diseases
Gene (Protein) Syndrome or Disease
Extracellular matrix protein genes
FBN1 (ﬁbrillin-1) Marfan syndrome
COL3A1 (type 3 procollagen) Vascular Ehlers-Danlos syndrome
COL4A5 (type 4 procollagen) Alport syndrome
EFEMP2 (ﬁbulin-4) Cutix laxa
TGF-b signaling pathway genes
TGFBR1 (TGF-b receptor-1) LDS or FTAAD
TGFBR2 (TGF-b receptor-2) LDS or FTAAD
SMAD3 (SMAD3) Osteoarthritis-aneurysm syndrome or LDS 3
TGFB2 (TGF-b2) FTAAD or LDS 4
SKI (v-SKI sarcoma oncogene homolog) Shprintzen-Goldberg syndrome
SLC2A10 (glucose transporter 10) Arterial tortuosity syndrome
Vascular smooth muscle contraction
components or cytoskeleton genes
ACTA2 (alpha-actin) FTAAD
MYH11 (myosin heavy chain-11) FTAAD
MLK (myosin light chain kinase) FTAAD
PRKG1 (protein kinase cGMP-dependent) FTAAD
FLNA (ﬁlamin A) Periventricular nodular heterotopia,
aortic aneurysm, valvular dystrophy
Adapted with permission from Pyeritz (1) and Lindsay and Dietz (2).
FTAAD ¼ familial thoracic aortic aneurysm and dissection; LDS ¼ Loeys-Dietz syndrome; TAA ¼ thoracic aortic
aneurysm; TGF ¼ transforming growth factor.
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1338phenotypic variability, a wide range of ages of
onset, and variable penetrance. For instance, among
families with ACTA2 mutations, the penetrance of
aortic disease is approximately 50% (6). In families
with TAA disease and no identiﬁable mutation, one
must continue to follow and perform imaging sur-
veillance in relatives.
A cursory physical examination is not enough to
determine risk.
Evaluating the patient with TAA disease requires
an understanding of features associated with these
conditions, which may inform the underlying diag-
nosis. This includes a careful family history inquiring
about facial dysmorphology, myopia, ocular lens
dislocation, premature cataracts, biﬁd uvula, spine
disease, pectus deformities, cleft palate, clubfoot,
pneumothorax, bicuspid aortic valve, cerebral aneu-
rysm, aortic or branch vessel aneurysm, patent duc-
tus arteriosus, premature vascular disease, aortic
dissection, or sudden death. Examining the patient
with TAA disease requires more than a cardiovascular
examination; one must examine the patient like a
dysmorphologist. Features signifying a potential
genetic aneurysm disorder include hypertelorism,
bluish sclera, abnormal uvula, dental crowding, tall
palate, malar hypoplasia, retrognathia, elongated
digits, pectus deformities, scoliosis, ﬂat feet, club
feet, joint contractures, hyperﬂexible joints, soft
velvety skin, hyperlucent skin, atrophic scars,abnormal bruising, and varicose veins. One cannot
expect all cardiologists or surgeons to become expert
in this evaluation, and partnering with an experi-
enced medical geneticist is recommended when
evaluating aneurysm syndromes and in interpreting
mutation analysis. Foundation websites provide
useful information on characteristics of many condi-
tions (7–9). Careful review of the computed tomog-
raphy or magnetic resonance imaging scan may
demonstrate arterial tortuosity, branch vessel en-
largement, or lumbosacral dural ectasia, all features
suggesting an underlying aortopathy syndrome.
Mutations in the gene encoding TGFB3 ligand,
TGFB3, were recently reported in 2 young patients
with skeletal features overlapping those seen with
Marfan syndrome and LDS (10,11). In this issue of the
Journal, an international coalition compiled clinical
and genetic information on 43 patients from 11
families with TGFB3 mutations (5). Importantly,
aortic aneurysms and dissections are new to the
constellation of features described in patients with
TGFB3 mutations. Advanced sequencing techniques
and mutation analysis were utilized. Prediction
modeling to assess the effects of alterations in TGFB3
function was performed. Histopathological examina-
tion of aortic wall specimens demonstrated elastic
ﬁber fragmentation of various degrees. Immunohis-
tochemical examination of aortic tissue revealed
increased TGF-b signaling in the aortic wall, differing
from the hypothesis proposed by Rienhoff et al. (10).
The phenotype of patients with TGFB3 mutations
includes many features recognized in LDS (due to
mutations in TGFB1 and 2) including hypertelorism,
biﬁd uvula, cleft palate, and clubfoot. Many patients
also have features present in MFS, such as high-
arched palate, pectus deformity, tall stature, hyper-
mobile joints, and arachnodactyly. No individuals
with TGFB3 mutations are reported as having ectopia
lentis (a feature discriminating for MFS). The authors
(5) highlight a striking interfamilial clinical variability
in phenotype, with some individuals having multiple
classic LDS features and others having none. This
emphasizes the importance of complete evaluation of
all ﬁrst-degree relatives and of mutation analysis,
even when outward features are not apparent.
The hallmark of initial reports of LDS as a result of
mutations in TGFBR1 and 2 included marked arterial
tortuosity and early and aggressive arterial disease,
such as aortic dissection at young age and relatively
small aortic dimensions (4). On the basis of this initial
report in the Journal, the vascular disease related to
TGFB3 mutations may have a less aggressive vascular
phenotype than LDS. Bertoli-Avella et al. (5) report
their cohort of patients as having a median age of
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133934 years (range 3 to 74 years), a median age of aortic
dissection of 47.5 years (range 30 to 80) years, and a
median age at death of 56 years (range 40 to 80 years)
(5). Unlike LDS, few patients in this cohort had branch
vessel disease. Distinct from LDS 1 and 2, TGFB3
mutations are not reported to lead to signiﬁcant
arterial tortuosity, which may be important because
the severity of arterial tortuosity has been associated
with aortic outcomes in other connective tissues
disorders (12). However, information from additional
patients will be necessary to more fully understand
the TGFB3 mutation spectrum and to predict aortic
and vascular risk among affected individuals.
The past several years have witnessed the dis-
covery of multiple gene mutations leading to aortic
aneurysm syndromes. Mutations in TGFB3 should be
added to the list of genes examined when evaluating
an individual with these features. Having evaluated
patients with heritable TAA syndromes, I am often
struck by how subtle the clinical ﬁndings may be.
Physical features, age of onset, and severity of
vascular disease may vary among affected familymembers. All mutated genes do not carry the same
degree of vascular risk. Not all patients with a gene
mutation may develop aortopathy leading to clinical
events. These issues present challenges for screening,
imaging surveillance, medical therapy, and recom-
mendations for timing of prophylactic aortic and
vascular surgery.
Many heritable TAA syndromes are relatively rare.
As reported by Dr. Bertoli-Avella et al. (5), the
phenotype of TGFB3 mutation disease overlaps with
those of other recognized heritable TAA disorders,
especially LDS. Collaboration among experts in the
ﬁeld is necessary to compile adequate experience in
the ever-increasing types of heritable TAA disease,
to detail natural history, and to inform management
decisions, especially regarding vascular disease.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Alan C. Braverman, Cardiovascular Division, Department
of Medicine, Washington University School of Medicine,
660 South Euclid Avenue, Box 8086, St. Louis, Missouri
63110. E-mail: abraverm@dom.wustl.edu.RE F E RENCE S1. Pyeritz RE. Heritable thoracic aortic disorders.
Curr Opin Cardiol 2014;29:97–102.
2. Lindsay ME, Dietz C. The genetic basis of aortic
aneurysm. Cold Spring Harb Perspect Med 2014;4:
a015909.
3. Doyle JJ, Gerber EE, Dietz HC. Matrix-
dependent perturbation of TGFb signaling and
disease. FEBS Lett 2012;586:2003–15.
4. Loeys BL, Schwarz U, Holm T, et al. Aneu-
rysm syndromes caused by mutations in the
TGF-b receptor. New Engl J Med 2006;355:
788–98.
5. Bertoli-Avella AM, Gillis E, Morisaki H, et al.
Mutations in a TGF-b ligand, TGFB3, cause syn-
dromic aortic aneurysms and dissections. J Am
Coll Cardiol 2015;65:1324–36.6. Guo DC, Papke CL, Tran-Fadulu V, et al. Muta-
tions in smooth muscle alpha-actin (ACTA2) cause
coronary artery disease, stroke and Moyamoya
disease, along with thoracic aortic disease. Am J
Hum Genet 2009;84:617–27.
7. The Marfan Foundation. Available at: http://
www.marfan.org. Accessed January 23, 2015.
8. Loeys-Dietz Syndrome Foundation. Available at:
http://www.loeysdietz.org/en. Accessed January
23, 2015.
9. TAD Coalition: Thoracic Aortic Disease. Avail-
able at: http://www.tadcoalition.org. Accessed
January 23, 2015.
10. Rienhoff HY Jr., Yeo CY, Morissette R, et al.
A mutation in TGFB3 associated with a syndrome
of low muscle mass, growth retardation, distal
arthrogryposis and clinical features overlappingwith Marfan and Loeys-Dietz syndrome. Am J Med
Genet A 2013;161A:2040–6.
11. Matyas G, Naef P, Tollens M, et al. De novo
mutation of the latency-associated peptide
domain of TGFB3 in a patient with overgrowth and
Loeys-Dietz syndrome features. Am J Med Genet A
2014;164A:2141–3.
12. Morris SA, Orbach DB, Geva T, et al. Increased
vertebral artery tortuosity index is associated with
adverse outcomes in children and young adults
with connective tissue disorders. Circulation 2011;
124:388–96.
KEY WORDS cytoskeleton, extracellular
matrix proteins, Loeys-Dietz syndrome,
Marfan syndrome, receptors, transforming
growth factor beta
